FDA approves Tukysa combination as first-line maintenance therapy for HER2-positive advanced breast cancer
The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for adults with HER2-positive advanced breast cancer.
The approval covers adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment and is supported by the Phase III HER2CLIMB-05 trial involving 654 patients.
The decision introduces an additional targeted maintenance treatment option for patients with advanced HER2-positive disease and expands the clinical role of tucatinib.
Field | Content |
Article Type | Approvals |
Drug Name | Tukysa |
Generic Name | Tucatinib |
Company | Pfizer |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | Expanded indication for first-line maintenance treatment |
Indication | Unresectable locally advanced or metastatic HER2-positive breast cancer |
Patient Population | Adults with HER2-positive advanced breast cancer following induction treatment |
Approved Regimen | Tucatinib plus trastuzumab and pertuzumab |
Therapy Area | Oncology; breast cancer |
Technology/Modality | Oral HER2-targeted tyrosine kinase inhibitor combined with HER2-directed monoclonal antibodies |
Clinical Study | Phase III HER2CLIMB-05 |
Study Population | 654 patients |
Treatment Setting | First-line maintenance following induction treatment |
Geography | United States |
What Happened | The FDA approved tucatinib in combination with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer. |
Why It Matters | The approval adds a targeted maintenance option in the first-line treatment pathway for advanced HER2-positive breast cancer. |
Supporting Context | The approval is supported by the Phase III HER2CLIMB-05 trial involving 654 patients. |
Potential Impact | The regimen could broaden treatment choices for eligible patients requiring continued HER2-directed therapy after induction treatment. |
Key Takeaway | Pfizer's Tukysa combination has received FDA approval for first-line maintenance treatment of advanced HER2-positive breast cancer. |
What to Watch | Clinical adoption, treatment sequencing, updated oncology guidelines and real-world outcomes following the approval. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 7 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments